SCHEMBL1965306

SCHEMBL1965306

CCCCCCn1c(=O)c(C(=O)OCC)c(O)c2cccn21

nearest known ligand 0.64

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.64
HTT P42858 2/20 0.64
KDM4E B2RXH2 6/20 0.57
LMNA P02545 2/20 0.57
L3MBTL1 Q9Y468 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.47
RECQL P46063 1/20 0.46
MAPK1 P28482 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MAPT P10636 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 1/20 0.41
PABPC1 P11940 1/20 0.41
USP2 O75604 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1967538 0.95 KDM4E (0.63) ALDH1A1HTTKDM4ELMNAL3MBTL1
SCHEMBL3761069 0.84 ALDH1A1 (0.51) ALDH1A1HTTKDM4ELMNAL3MBTL1
SCHEMBL1967350 0.81 KDM4E (0.54) ALDH1A1HTTKDM4ELMNASMN1; SMN2
SCHEMBL1972746 0.79 MEN1 (0.47) ALDH1A1HTTKDM4ELMNASMN1; SMN2
SCHEMBL1967127 0.79 KDM4E (0.48) ALDH1A1HTTKDM4ELMNARECQL
SCHEMBL1980308 0.78 TDP1 (0.50) ALDH1A1HTTKDM4ELMNASMN1; SMN2
SCHEMBL8361521 0.78 ALDH1A1 (1.00) ALDH1A1HTTKDM4ELMNAL3MBTL1
SCHEMBL8357959 0.78 ALDH1A1 (1.00) ALDH1A1HTTKDM4ELMNAL3MBTL1
SCHEMBL1965910 0.78 ALDH1A1 (0.47) ALDH1A1HTTKDM4ELMNAL3MBTL1
SCHEMBL1966882 0.78 ALDH1A1 (0.46) ALDH1A1HTTKDM4ELMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334682-B1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN INC (US) 2017-10-04 EP disclosed
US-8217043-B2 Compounds and methods for their use FIBROGEN, INC. (US) 2012-07-10 US disclosed
EP-2334682-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS Fibrogen, Inc. (US) 2011-06-22 EP disclosed
WO-2010022240-A1 PYRROLO [ 1, 2 -B] PYRIDAZINE DERIVATIVES AND THEIR USE AS HIF MODULATORS FIBROGEN, INC. (US) 2010-02-25 WO disclosed
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE FIBROGEN, INC. 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100047367-A1 COMPOUNDS AND METHODS FOR THEIR USE HIF1AN, HIF1A, EGLN3 ALDH1A1 268/4885HTT 1833/4885KDM4E 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.